Related by context. All words. (Click for frequent words.) 79 HBeAg positive 75 relapsed MM 74 leukemia AML 73 CYT# potent vascular disrupting 72 K ras mutations 72 recurrent glioblastoma multiforme 72 hypereosinophilic syndrome 72 stage IIIB 72 metastatic malignant 72 chronic eosinophilic leukemia 72 Lymphocytic 71 ribavirin therapy 71 Ribavirin causes 71 metastatic malignant melanoma 71 candidemia 71 myelodysplastic myeloproliferative diseases 71 BARACLUDE ® 71 TTR amyloidosis 71 ADPKD 71 grade cervical intraepithelial 71 NMIBC 71 genotypic resistance 71 Leukemias 71 e antigen HBeAg 71 decompensated liver disease 71 invasive candidiasis 71 basal cell carcinoma BCC 71 hypophosphatemia 70 completely resected 70 Amgen Neulasta R 70 NRTI resistance 70 stage IIIb IV 70 Sezary syndrome 70 unresectable tumors 70 mRCC 70 severe neutropenia 70 chronic HCV 70 systemic autoimmune 70 gastric adenocarcinoma 70 PAOD 70 tipranavir ritonavir 70 anthracycline containing 70 recurrent metastatic 70 posterior uveitis 70 hepatorenal syndrome 70 chronic HCV genotype 70 nonmetastatic 70 baseline LDH 70 papillary renal cell carcinoma 70 chronic HBV 70 Acute myeloid leukemia 70 lupus erythematosus 70 Naive Patients 70 protease inhibitor PI 70 antiretroviral naïve 70 recurrent genital herpes 70 FluCAM arm 70 smoldering multiple myeloma 69 intestinal metaplasia 69 HIV uninfected 69 nonmelanoma skin cancers 69 HIV coinfected 69 leukemia CLL 69 neutropenia dehydration dyspnea 69 intracranial hemorrhage ICH 69 hematologic toxicity 69 Relapsing remitting MS 69 headache abdominal pain 69 posaconazole 69 metastatic neuroendocrine tumors 69 HBeAg + 69 ritonavir boosted 69 histologically confirmed 69 complement inhibitor eculizumab 69 osteosarcomas 69 deletion 5q 69 APTIVUS r 69 nonalcoholic steatohepatitis NASH 69 refractory chronic lymphocytic 69 KRAS mutations occur 69 latent tuberculosis infection 69 cell lymphoma CTCL 69 PREZISTA r 69 orchitis 69 chronic HCV infection 69 CIN3 69 metastatic GIST 69 LymphoStat B belimumab 69 Cutaneous T 69 proctitis 69 pediatric acute lymphoblastic 69 epithelial tumors 69 hepatocellular carcinomas 69 pheochromocytoma 69 C1 INH deficiency 69 methicillin susceptible Staphylococcus aureus 69 Peginterferon alfa 2b 69 squamous histology 69 UGT#A# * 69 cirrhosis liver failure 69 lenalidomide Revlimid R 69 HER2 overexpression 69 tumors GIST 69 hepatitis C genotype 69 Chronic Hepatitis C 69 lymphocytosis 69 TEAEs 69 3TC lamivudine Epivir 69 SPRYCEL ® 69 hyperphenylalaninemia HPA due 69 discontinued Viread 68 lamivudine resistant 68 herpes zoster shingles 68 Squamous 68 ALT flares 68 transaminase elevations 68 chronic HBV infection 68 ara C 68 genotype 1b 68 metastatic bladder 68 vWD 68 FOLFOX6 68 coinfected patients 68 hemorrhagic cystitis 68 nucleoside analog 68 neurological manifestations 68 NOMID 68 CLL SLL 68 trastuzumab Herceptin ® 68 macroalbuminuria 68 lichen planus 68 seropositive patients 68 nucleoside naive 68 AGILECT R 68 familial amyloidotic polyneuropathy FAP 68 Candida infection 68 ANCA associated 68 neutropenia thrombocytopenia 68 intravenous bisphosphonates 68 LHRH receptor positive 68 HBeAg 68 C. trachomatis 68 castrate resistant 68 SSc 68 basal cell nevus syndrome 68 non alcoholic steatohepatitis 68 candidiasis 68 alanine aminotransferase ALT 68 HIV HCV coinfected 68 elevated LDH 68 coinfected 68 Nonalcoholic fatty liver 68 K#N 68 biologic DMARD 68 forodesine 68 lamivudine refractory patients 68 invasive aspergillosis 68 mycosis fungoides 68 overt nephropathy 68 SGPT 68 FOLFIRI alone 68 abacavir Ziagen 68 orally administered inhibitor 68 Opportunistic infections 68 voriconazole 68 elevated ALT 68 heavily pretreated 68 histological subtype 68 metastatic hormone refractory 68 situ CIS 68 deep venous thromboses 68 adjunctive placebo 68 -#.# log# 68 comparator arm 68 liver metastasis 68 CC genotype 68 dopaminergic therapy 68 Amgen Neulasta ® 68 chronic myeloid 68 myelofibrosis polycythemia vera 68 8mg/kg 68 â ‰ ¥ 68 atypical hemolytic uremic syndrome 68 immunomodulatory therapy 68 leukemia ALL 68 cytopenias 68 pegylated interferon alfa 2a 68 metastatic castration resistant 68 anthracycline taxane 68 pyrexia mucositis sepsis febrile 68 recurrent glioblastoma 68 metastatic gastric 68 Aflibercept 67 ribavirin RBV 67 cervical intraepithelial neoplasia 67 Flu Cy 67 gemcitabine carboplatin 67 histologically proven 67 HBeAg positive patients 67 severe renal impairment 67 adenomatous polyps 67 Chronic lymphocytic leukemia 67 Mg Uk 67 Pneumocystis carinii pneumonia 67 essential thrombocythemia 67 elevated serum creatinine 67 Metastatic breast cancer 67 follicular lymphoma FL 67 Myelodysplastic Syndrome MDS 67 essential thrombocythemia ET 67 antiangiogenic therapy 67 lopinavir r arm 67 autoantibody positive 67 proliferative diabetic retinopathy 67 advanced hepatocellular carcinoma 67 corticosteroid therapy 67 anemia neutropenia 67 ABCB1 67 % CI #.#-#.# [007] 67 oropharyngeal candidiasis OPC 67 adalimumab Humira 67 skeletal metastases 67 neoplasias 67 HBeAg negative chronic hepatitis 67 recurrent VTE 67 taxane resistant 67 histologic subtype 67 HBeAg seroconversion 67 placebo dexamethasone 67 pemphigus vulgaris 67 immunocompetent 67 biochemical relapse 67 HBeAg negative patients 67 novel VDA molecule 67 T2DM 67 recurrent NSCLC 67 alfa 2a 67 ORENCIA ® 67 cisplatin chemotherapy 67 kidney urologic 67 CIMZIA ™ 67 erlotinib Tarceva ® 67 virologic responses 67 smoldering myeloma 67 lenalidomide dexamethasone 67 AZT zidovudine Retrovir 67 oral nucleoside analogue 67 immunosuppressed patients 67 plus methotrexate 67 AML MDS 67 diabetic kidney 67 HBV infections 67 Epstein Barr virus EBV 67 epithelioid 67 CIMZIA TM certolizumab pegol 67 unresectable stage 67 Pharmacokinetics PK 67 PROSTVAC VF 67 tumor xenograft models 67 liver scarring 67 FUSILEV enhances 67 colorectal adenoma 67 HPV subtypes 67 CTAP# 67 Papillary 67 colorectal carcinoma 67 atrophic gastritis 67 adriamycin 67 patients coinfected 67 immunocompetent patients 67 NNRTI resistance 67 leukemia APL 67 urothelial carcinoma 67 weekly subcutaneous injections 67 interferon alfa 67 Peginterferon Alfa 2a 67 Peg IFN 67 pulmonary metastasis 67 squamous cell carcinoma SCC 67 metastatic RCC 67 Non Alcoholic Steatohepatitis 67 interferon ribavirin 67 sorafenib tablets 67 reduce serum phosphate 67 Infusion Reactions Severe 67 sJIA 67 Acute Bacterial Sinusitis ABS 67 monoinfected patients 67 resistant hormone refractory 67 systemic fungal infections 67 myeloproliferative neoplasms 67 non splenectomized 67 prostate cancer CaP 67 ethambutol 67 pT3 67 ovarian carcinoma 67 relapsed leukemia 67 curative resection 67 mcg albinterferon alfa 2b 67 4mg/kg 67 liposomal amphotericin B 67 cyclophosphamide methotrexate 67 peginterferon alfa 67 relapsed ALL 67 dasatinib Sprycel ® 67 MALT lymphoma 67 CCR5 tropic HIV 67 TNF blocker therapy 67 seronegative 67 Renal Cell Carcinoma RCC 67 cancer mCRC 67 clodronate 67 fluconazole resistant 67 minimally symptomatic 67 elevated transaminases 67 advanced adenomas 67 LV dysfunction 67 MAGE A3 ASCI 67 neovascular diseases 67 abacavir lamivudine 67 hypercalcemia 67 ug dose 67 hepatic metastases 67 small lymphocytic lymphoma 67 nonalcoholic steatohepatitis 67 liver histology 67 post transplant lymphoproliferative 67 micafungin 67 malignant neoplasm 67 cutaneous T 67 ErbB2 positive 67 Hurthle cell 67 myelodysplastic syndrome MDS 67 Surgical resection 67 syngeneic 67 HeFH 67 CTAP# Capsules 67 Acute myelogenous leukemia 66 mild renal insufficiency 66 Severe Primary IGFD 66 docetaxel Taxotere ® 66 RhuDex ® 66 ALT normalization 66 HBV genotype 66 alpha interferons 66 advanced adenoma 66 Idiopathic pulmonary fibrosis 66 efalizumab 66 de novo AML 66 squamous 66 BRAF V#E 66 amoxicillin clavulanate 66 galiximab 66 Soft Tissue Sarcoma 66 hematopoietic cancers 66 coinfection 66 alanine aminotransferase 66 aplastic anemia AA 66 CR nPR 66 flutamide 66 SJIA 66 thalidomide Thalomid 66 receiving VELCADE 66 unresectable recurrent 66 acquired immunodeficiency syndrome 66 hepatocellular cancer 66 J Am Coll 66 severe oral mucositis 66 Refractory Hodgkin Lymphoma 66 Adjuvant chemotherapy 66 BENICAR HCT 66 pyrazinamide 66 chronic GVHD 66 elevated triglyceride levels 66 idiopathic PAH 66 AA Amyloidosis 66 Hematologic 66 % CI #.#-#.# [003] 66 diabetes mellitus DM 66 CsA 66 CMV disease 66 thrombocytopenic 66 Complicated Skin 66 DEB# 66 treatment naive genotype 66 mitoxantrone plus 66 gastric carcinoma 66 achieved ACR# 66 corticosteroid dexamethasone 66 interstitial pneumonitis 66 ano genital warts 66 refractory Hodgkin 66 hematologic disorders 66 hereditary predisposition 66 non squamous NSCLC 66 Lipodystrophy 66 interferon alfa 2a 66 generalized edema 66 T1DM 66 pneumocystis carinii pneumonia 66 cholangiocarcinoma 66 progressive dyspnea 66 HCV genotype 66 receiving immunosuppressive therapy 66 Balamuthia 66 receiving XGEVA 66 acute myeloid 66 mutated K ras 66 leucopenia 66 budesonide foam 66 octreotide LAR 66 chlorambucil 66 tuberculin skin testing 66 pulmonary metastases 66 chronic hepatitis cirrhosis 66 poor metabolizers 66 Non Alcoholic Fatty 66 T1c 66 acute GvHD 66 virologic breakthrough 66 differentiated thyroid 66 metastatic pancreatic 66 ceftazidime 66 genital ulcer 66 leukopenia 66 R Saizen R 66 CMV retinitis 66 hepatitis C HCV 66 prolonged QT interval 66 ACTEMRA TM 66 hepatoma 66 T#I [002] 66 polycythemia vera essential thrombocythemia 66 Pegylated Interferon 66 toenail onychomycosis 66 metastatic renal cell carcinoma 66 pegylated liposomal doxorubicin 66 nevirapine Viramune 66 Bronchiectasis 66 virologic failure 66 mitoxantrone chemotherapy 66 prostate carcinoma 66 HER2 expression 66 vaginal candidiasis 66 included exfoliative dermatitis 66 System IPSS 66 null responder 66 TMP SMX 66 pancreatic adenocarcinoma 66 null responder HCV 66 diarrhea predominant irritable 66 Pemetrexed 66 Epratuzumab 66 5-FU/LV 66 Hashimoto thyroiditis 66 TNF antagonist 66 TT genotype 66 tigecycline 66 acute leukemias 66 invasive lobular 66 endocrine therapies 66 cytoreduction 66 castrate resistant prostate cancer 66 minimally symptomatic metastatic castrate 66 Lubiprostone 66 refractory gout 66 alkylating agent 66 ß blockers 66 Venous thromboembolism 66 leiomyomas 66 Carcinoid tumors 66 CIN2 + 66 thromboembolic complications 66 See WARNINGS 66 varicella zoster virus VZV 66 β blocker 66 TTR gene 66 indinavir 66 microbiologically evaluable 66 locoregional recurrence 66 vincristine doxorubicin 66 cervical lymph nodes 66 proliferative retinopathy 66 plus OBT 66 idarubicin 66 Folfox 66 Navelbine ® 66 #mg BID [001] 66 Mg Usa 66 unresectable 66 ertapenem 66 cirrhotic 66 underwent surgical resection 66 moderate renal impairment 66 receptor tyrosine kinase inhibitor 66 antiretroviral naive 66 Trichomonas vaginalis 66 haematologic 66 relapsing remitting MS RRMS 66 cutaneous squamous cell carcinoma 66 achieved CCyR 66 oral vancomycin 66 trastuzumab Herceptin R 66 MGUS 66 cytomegalovirus infection 66 invasive ductal 66 CrCl 66 R5 tropic 66 mCRPC 66 Chronic pancreatitis 66 Castration Resistant Prostate Cancer 66 bacteremic pneumonia 66 ritonavir boosted protease inhibitor 66 hepatic failure 66 somatostatin analog 66 thalassemia sickle cell 66 virus HCV 66 BCG refractory carcinoma 66 node metastases 66 gastrointestinal stromal tumor GIST 66 bridging fibrosis 66 VELCADE melphalan 66 APTIVUS 66 refractory cutaneous T 66 purpura ITP 66 TYGACIL 66 STELARA TM 66 benazepril 66 Acute Myeloid Leukaemia AML 66 N. gonorrhoeae 66 erythema nodosum 66 Systemic lupus erythematosus SLE 66 fallopian tube carcinoma 66 Stage IIIb 65 paclitaxel cisplatin 65 cell acute lymphoblastic 65 nasopharyngeal carcinoma 65 saline placebo 65 squamous cell lung cancer 65 nicardipine 65 pyridostigmine 65 COPEGUS ribavirin 65 visceral metastases 65 mucinous 65 B Cell Lymphoma 65 distant metastasis 65 unknown etiology 65 Atypical Hemolytic Uremic Syndrome 65 Relapsed Refractory 65 humanized interleukin 6 65 oesophageal adenocarcinoma 65 Follicular Lymphoma 65 morphometric vertebral fractures 65 severe malignant osteopetrosis 65 Genotypes 65 autoimmune thyroid 65 refractory metastatic 65 metaplasia 65 lopinavir r 65 umol L 65 psoriatic arthritis PsA 65 Fludarabine 65 refractory anaplastic astrocytoma 65 miconazole Lauriad ® 65 ATTR 65 indinavir Crixivan 65 TDF FTC 65 subependymal giant cell 65 external genital lesions 65 EGFR HER2 65 pancreatic prostate 65 unfavorable cytogenetics 65 Gorlin syndrome 65 mg q#h 65 Toxicities 65 chemotherapy cisplatin 65 induce orthostatic hypotension 65 HNSCC 65 leukemia multiple myeloma 65 systemic anaplastic large 65 dirucotide MBP# 65 lipid abnormalities 65 relapsed acute myelogenous 65 cetuximab Erbitux R 65 neutropaenia 65 prior chemotherapy regimens 65 histologies 65 cranial irradiation 65 metastatic renal 65 NS5b 65 precursor lesions 65 del 5q MDS 65 mycophenolate mofetil 65 virus HCV infection 65 liver decompensation 65 keloid scarring 65 INCB# [003] 65 endometrial hyperplasia 65 Albuferon TM 65 RhuDex ™ 65 VP# [004] 65 gastrointestinal stromal tumors GIST 65 breast carcinomas 65 atypical Hemolytic Uremic Syndrome 65 transaminase levels 65 urethritis 65 transplantation HCT 65 bullous 65 nucleotide analogue 65 lymphopenia 65 selective modulator 65 liver transplant recipients 65 tenofovir emtricitabine 65 pT2 65 pulmonary hypertension PH 65 Chlamydia trachomatis 65 nonsmall cell lung cancer 65 anti PlGF 65 Virulizin ® 65 conventional DMARDs 65 neuroendocrine cancers 65 rheumatoid arthritis RA psoriatic 65 lintuzumab SGN 65 zidovudine AZT 65 postmenopausal osteoporotic women 65 nonnucleoside reverse transcriptase inhibitors 65 tamoxifen Nolvadex ® 65 IGFD 65 CMV infection 65 efavirenz EFV 65 EGFR TKI 65 carcinoma HCC 65 antibody MAb 65 cystic fibrosis chronic pancreatitis 65 Chlamydia trachomatis infection 65 breast endometrial 65 autoantibody levels 65 androgen deprivation 65 doxorubicin cyclophosphamide 65 Postoperative complications 65 clinically evaluable 65 trimethoprim sulfamethoxazole 65 commercialize deforolimus 65 pyelonephritis 65 Decitabine 65 lymphoproliferative disorders 65 carcinoid syndrome 65 chronic periodontitis 65 PLX STROKE targeting 65 COPEGUS R 65 alpha1 antitrypsin AAT deficiency 65 bexarotene 65 relapsing remitting 65 nucleoside analogue 65 progesterone receptor negative 65 dexrazoxane 65 simplex virus 65 telaprevir dosed 65 precancerous condition 65 Pegylated interferon 65 PEGINTRON TM 65 mcg BID 65 receiving prophylactic anticoagulation 65 sulfasalazine 65 G CSFs 65 genital ulcers 65 oral antidiabetic medication 65 NNRTI resistant virus 65 virological failure 65 anterior uveitis 65 eosinophilic asthma 65 idiopathic thrombocytopenic purpura 65 Herpes zoster 65 PsA 65 Peginterferon 65 Irinotecan 65 Adenomas 65 RhuDex TM 65 PREZISTA r arm 65 bladder ovarian 65 INSPIRE Trial Phase III 65 seropositivity 65 antiandrogens 65 PEG IFN 65 refractory anemia RA 65 overt hypothyroidism 65 IV NSCLC 65 lumiliximab 65 MCyR 65 pyrimethamine 65 hematological parameters 65 follicular lymphomas 65 methotrexate monotherapy 65 inhibitor RG# 65 Acute myeloid leukemia AML 65 Glioblastoma Multiforme 65 GISTs 65 fluvastatin 65 mcg kg REBETOL 65 allogeneic HSCT 65 allogeneic bone marrow 65 Thal Dex 65 hyperplasia BPH 65 gastric atrophy 65 HER2 positive metastatic breast 65 chronic granulomatous disease 65 primary hypercholesterolemia 65 TKI therapy 65 Torsades de Pointes 65 Neovascular AMD 65 carcinoid tumors 65 oncogenic HPV 65 intravesical therapy 65 breast carcinoma 65 refractory CLL 65 adverse cytogenetics 65 BEXXAR Therapeutic Regimen 65 G6PD deficiency 65 Gilead Viread 65 RRMS patients 65 colorectal liver metastases 65 renal tumors 65 mg/m2 dose 65 erosive gastritis 65 rFVIIa 65 hormone refractory 65 carcinoid 65 aminotransferases 65 decompensated cirrhosis 65 Subgroup analysis 65 Lupus nephritis 65 enterocolitis 65 #mg/m# [001] 65 lipid lowering agents 65 P aeruginosa 65 hormone receptor negative 65 PegIFN RBV 65 ganciclovir 65 IFN alfa 65 Fibrillex TM 65 haloperidol Haldol 65 rheumatoid arthritis osteoarthritis ankylosing 65 virus HCV protease inhibitor 65 lymphocytic 65 renal cell carcinomas 65 MKC# MT 65 Staphylococcus aureus infections 65 pegylated interferon alpha 65 combination antiretroviral therapy 65 IPAH 65 Hepatitis B Virus 65 efavirenz Sustiva 65 febrile neutropenia 65 Patients Treated With 65 CHOP chemotherapy 65 piperacillin tazobactam 65 EGFR mutation positive 65 CIMZIA TM 65 headache nasopharyngitis 65 INVANZ 65 corticosteroid dose 65 receiving VICTRELIS 65 Asymptomatic 65 aminotransferase levels 65 HCV genotypes 65 S/GSK# 65 diphtheria pertussis whooping cough 65 chronic hepatitis B. 65 PREZISTA ritonavir 65 renal allograft 65 relapsed refractory multiple myeloma 65 CP CPPS 65 Sjögren syndrome 65 Genital herpes 65 calcineurin inhibitor 65 KRAS wild 65 NNRTIs 65 Epidermal Growth Factor Receptor 65 myocardial infarction ventricular fibrillation 65 evaluating tivozanib 65 ARCALYST ® 65 thyrotoxicosis 65 interferon alfa 2b 65 interferon gamma 1b 65 Kinoid 65 treatment naïve genotype 65 placebo PBO 65 taxane chemotherapy 65 cervical carcinoma 65 cervicitis 65 Basal Cell 65 pancreatic insufficiency 65 H pylori 65 cutaneous melanoma 65 oral thrush 65 Investigational Treatment 65 Chronic HCV 65 anemia hemoglobin 65 Chronic myeloid leukemia 65 haematological malignancies 65 CTEPH 65 Lung transplantation 65 RhuDex R 65 malignant neoplasms 65 pioglitazone HCl 65 invasive carcinomas 65 sunitinib Sutent 65 ALN HPN 65 KRAS mutations 65 Waldenstrom macroglobulinemia 64 metastatic colorectal 64 PSA nadir 64 Combination therapy 64 imipenem 64 refractory chronic myeloid 64 Hormone Refractory Prostate Cancer 64 imatinib therapy 64 torsade de pointes 64 cefuroxime 64 neoplastic lesions 64 serum aminotransferase levels 64 HLA DR2 64 colorectal adenocarcinoma 64 investigational monoclonal antibody 64 thymoma 64 CYP#A# CYP#D# 64 tipranavir r 64 rs# [001] 64 Pseudomonas aeruginosa infections 64 mediastinitis 64 apolipoprotein E4 64 PEGylated Fab fragment 64 chemotherapy induced neutropenia 64 arthritis PsA 64 biliary tract cancer 64 neutropenic patients 64 ductal breast cancer 64 CIN2 64 hyperparathyroidism 64 chronic immune thrombocytopenic 64 Adenoviral 64 membranous nephritis 64 GSTP1 64 adenocarcinomas 64 hepatic fibrosis 64 FLT3 64 ulcerative colitis Crohn disease 64 Benign breast 64 STELARA ® 64 anaphylactic reactions bronchospasm 64 lymphoid malignancies 64 heFH 64 colorectal carcinomas 64 rs# [002] 64 late onset Pompe 64 Paraplatin ® 64 evaluable subjects 64 canakinumab 64 enalapril 64 homozygous familial hypercholesterolemia 64 medically inoperable 64 overt hepatic encephalopathy HE 64 hepatocellular carcinoma liver 64 cytotoxic therapy 64 HLA DRB1 * 64 peginterferon 64 IBS C 64 surgically resectable 64 invasive fungal infections 64 alvespimycin 64 metastatic renal cell 64 leukaemias 64 infliximab monotherapy 64 HCV genotype 1 64 peginterferon alfa 2a Pegasys 64 undetectable HBV DNA 64 clade B 64 Hepatocellular Carcinoma HCC 64 certolizumab 64 relapsed Acute Myeloid 64 operable breast cancer 64 bacterium Neisseria meningitidis 64 virologically suppressed 64 erythematosus 64 secondary hyperparathyroidism 64 idiopathic myelofibrosis 64 adjunctive ABILIFY 64 anogenital warts 64 genotype 1a 64 superficial basal cell carcinoma 64 aphthous stomatitis 64 p# biomarker 64 chlamydial infection 64 R entecavir 64 cytologically confirmed 64 rheumatoid arthritis inflammatory bowel 64 normal karyotype 64 salmeterol fluticasone 64 parasitemia 64 gefitinib Iressa 64 Elotuzumab 64 stage IIIB IV 64 HGS ETR1 mapatumumab 64 hamartomas 64 Lenocta 64 unresectable HCC 64 serum phosphate 64 pegIFN 64 Patients Receiving 64 Colon polyps 64 refractory acute myeloid 64 basal bolus regimen 64 nodal metastasis 64 onset diabetes mellitus 64 thrombocytopenia neutropenia 64 NATRECOR ® 64 imatinib Gleevec ® 64 alemtuzumab treated 64 hemodynamically significant 64 KRAS mutant tumors 64 tumor lysis syndrome 64 ovarian breast 64 anthracyclines taxanes 64 signal transduction inhibitors 64 Fanconi syndrome 64 dose cohort 64 Cytomegalovirus CMV 64 hemorrhagic complications 64 PEGylated interferon beta 1a 64 cryptococcal meningitis 64 antibody titer 64 sustained virologic response 64 FLT3 mutations 64 superficial bladder cancer 64 atypical ductal hyperplasia 64 relapsed AML 64 acute humoral rejection 64 neoplasia CIN 64 malignant fibrous histiocytoma 64 Stage IIB 64 Nilotinib 64 MYLOTARG 64 bacteriuria 64 ALN TTR 64 SUPPRELIN R LA 64 vitreous floaters 64 Enterobacter cloacae 64 stavudine d4T 64 gastrointestinal stromal tumors GISTs 64 Diffuse Large B 64 MELAS 64 metastatic androgen independent 64 hepatotoxicity 64 metastatic castrate resistant 64 Fludara ® 64 post thrombotic syndrome 64 GnRH agonist 64 entecavir 64 pamidronate 64 rFSH 64 myopathy rhabdomyolysis 64 polycythemia vera PV 64 oxacillin 64 Adefovir 64 targeting miR 64 interleukin IL -# 64 severe rotavirus gastroenteritis 64 Bisphosphonate 64 ASCUS 64 unstable angina UA 64 EXJADE 64 lupus nephritis 64 anal HPV 64 μg doses 64 oligodendrogliomas 64 Crohn disease CD 64 Gleevec resistant 64 neuroblastoma tumors 64 phase IIb study 64 prokinetic agent 64 Aortic stenosis 64 NRTI backbone 64 riociguat 64 GABHS 64 localized renal 64 malignancy HCM 64 MYH9 gene 64 Pooled Analysis 64 fluoropyrimidine 64 Doxil ® 64 nucleoside analogues 64 arterial thromboembolic 64 vidofludimus 64 pouchitis 64 underwent resection 64 ritonavir boosted atazanavir 64 dengue haemorrhagic fever DHF 64 recurrent DVT 64 Plasmodium ovale